INCEPTA Pharmaceuticals
Ltd is proud to become one of the 27 companies to sign licensing
agreement with the Medicines Patent Pool (MPP) to manufacture the
generic version of the oral COVID-19 antiviral medication Molnupiravir
for supply in 105 low- and-middle-income countries (LMICs).
Premia Biotech Ltd
Mobile / WhatsApp : +44 7887 477007
Email : info@premiabiotech.com
https://lnkd.in/gZTzg-pW
#covid #molnupiravir #genericdrugs #antiviral #pharmaceuticalsales #premiabiotech
A great company to deal with, extremely reliable with a good range of products. Excellent product knowledge, great communication & customer service, fair prices and fast delivery.